Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBITDA: 2020-2024

Historic EBITDA for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$91.5 million.

  • Taysha Gene Therapies' EBITDA fell 31.38% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 16.36%. This contributed to the annual value of -$91.5 million for FY2024, which is 26.26% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported EBITDA of -$91.5 million as of FY2024, which was down 26.26% from -$72.4 million recorded in FY2023.
  • Taysha Gene Therapies' EBITDA's 5-year high stood at -$43.0 million during FY2020, with a 5-year trough of -$173.3 million in FY2021.
  • Moreover, its 3-year median value for EBITDA was -$91.5 million (2024), whereas its average is -$108.8 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' EBITDA plummeted by 302.93% in 2021, and later spiked by 55.41% in 2023.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' EBITDA stood at -$43.0 million in 2020, then slumped by 302.93% to -$173.3 million in 2021, then grew by 6.24% to -$162.4 million in 2022, then skyrocketed by 55.41% to -$72.4 million in 2023, then declined by 26.26% to -$91.5 million in 2024.